Quick Answer
Design Therapeutics, Inc. reported Cash and Equivalents of $16.86 million for fiscal year 2025.
Design Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $16.86M | -25.3% |
| 2024 | $22.56M | +6.4% |
| 2023 | $21.20M | -20.0% |
| 2022 | $26.50M | -91.1% |
| 2021 | $298.57M | +12450.2% |
| 2020 | $2.38M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $15.09M | -50.3% | -23.4% |
| June 30, 2025 | $19.70M | -56.9% | +44.2% |
| March 31, 2025 | $13.67M | -53.5% | -39.4% |
| December 31, 2024 | $22.56M | +6.4% | -25.6% |
| September 30, 2024 | $30.33M | +8.5% | -33.6% |
| June 30, 2024 | $45.70M | +68.0% | +55.5% |
| March 31, 2024 | $29.40M | +2.0% | +38.7% |
| December 31, 2023 | $21.20M | -20.0% | -24.1% |
- Design Therapeutics, Inc. showed a decrease of -25.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Design Therapeutics, Inc.’s cash and equivalents has grown by 608.5% (from $2.38 million to $16.86 million).
- The most recent figure is from Design Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: